CGI 2026: A Path Forward for Neglected Disease Research
Jared Bauer reflects on CGI 2026 and Open Impact, Seek Labs’ three-year commitment to advance research on neglected and underserved infectious diseases.
Archive
All News
Every update, milestone, and publication from Seek Labs.
-
-
Seek Labs Launches Open Impact Program at Clinton Global Initiative to Advance Therapeutic Development for Neglected Infectious Diseases
Seek Labs has launched the Open Impact Sequence Ablation Therapeutics Program, a new Clinton Global Initiative Commitment to Action designed to advance therapeutic development for neglected and underserved infectious diseases using BioSeeker AI and Sequence Ablation Therapeutics.
-
How Better Antiviral Tactics Could Counter Antimicrobial Resistance
It’s a scenario that happens across the world, and it’s a major driver of antibiotic resistance. A patient wanders into a clinic with a sore throat or coughing and congested. The doctor knows the sore throat or respiratory infection is likely caused by a virus, which antibiotics can’t kill, but today’s diagnostic tools don’t allow…
-
Seek Labs Takes First Place in BioTech and Therapeutics at 2026 Utah Business Innovation Awards
Seek Labs received first place in the BioTech and Therapeutics category of the 2026 Utah Business Innovation Awards for its novel Sequence Ablation Therapeutics (SAT) modality.
-
NAMRU EURAFCENT Partners with Seek Labs to Advance Field-Deployable Technologies for Warfighter Readiness
In May, Naval Medical Research Unit (NAMRU) EURAFCENT entered into two cooperative research and development agreements (CRADAs) with Seek Labs.
-
Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious Diseases
Seek Labs and NAMRU EURAFCENT have entered a CRADA to evaluate field-deployable molecular diagnostics for infectious disease detection and biosurveillance.
-
AI Can Design Viruses. Can Our Defenses Adapt Fast Enough?
AI-designed viruses are becoming a reality. Learn how programmable CRISPR could help build faster defenses against emerging and engineered viral threats.
-
From ANINA to SeekIt: What a chemistry breakthrough becomes when it is built into a platform.
From ANINA to SeekIt: What a chemistry breakthrough becomes when it is built into a platform. How Seek Labs is turning a new amplification mechanism into a configurable diagnostic platform for respiratory disease and biosecurity By Jared Bauer, CEO and Co-Founder, Seek Labs | Part 2 of a series on Seek Labs’ ANINA chemistry SeekIt™…
-
ANINA: Molecular Accuracy Without the Laboratory.
Discover how Seek Labs developed ANINA™, a novel isothermal amplification chemistry for molecular accuracy without laboratory infrastructure.
-
Seek Labs Announces Publication in Nature Communications Validating ANINA™, a Room-Temperature, Instrument-Free Amplification Diagnostic Technology Designed to Deliver PCR-Level Sensitivity at the Point of Need
Data support SeekIt™, the Company’s molecular diagnostic platform’s, potential to eliminate the long-standing tradeoff between molecular performance, speed and accessibility.
-
Annexing isothermal nucleotide amplification enables probe-guided amplification and direct detection at ambient temperature
Isothermal nucleic acid amplification offers advantages over qPCR for decentralized diagnostics but remains constrained by rigid primer design, detection complexity, and equipment dependence.
-
BIO 2026: Where Pharma Leaders say AI Hasn’t Delivered
BIO 2026: Where Pharma leaders Say AI Hasn’t Delivered This article was written by Meagan Parrish and originally published on PharmaVoice.com on June 26, 2026. Read the original story here. AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.…
Stay connected
Follow the work as it unfolds.
Stay connected to company milestones, scientific insights, and the work unfolding across BioSeeker, SAT, and Seek Diagnostics.